Endpoints News
Acadia’s Alzheimer's psychosis failure Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T W Thu F
24 September, 2026
The Lantern Summit: Shanghai, October 26-27, 2026. Request an invitation.
Build your next China biotech partnership at Lantern Summit, October 26-27 in Shanghai. Early-bird pricing ends September 27.
sponsored by The Lantern Summit
presented by Clinical Enrollment
Every­body op­ti­mizes the first 20% of pa­tient re­cruit­ment. Tri­als fall apart in the oth­er 80%.
spotlight
top stories
1. Merck’s return to ophthalmology snags first success
2. Acadia drug fails mid-stage study in Alzheimer's psychosis, leading to modified Phase 3
3. Roche secures separate discovery deals with Atavistik, Earendil 
4.
news briefing
Sarepta to pay Regenxbio $39M to settle gene therapy claims; Vida eyes fourth fund
5. In another China pact, Lilly makes a deal with InnoCare worth up to $3.35B
6. Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T
7. FDA adcomm votes in favor of benefit-risk of Grail’s cancer test
more stories
• 
in focus
Karen Weintraub
.

Merck reported good efficacy news in a diabetic macular edema trial, beginning to justify its $1.3 billion upfront investment in EyeBio two years ago. But safety concerns were raised, too, as Kyle LaHucik reports.
.
Karen Weintraub
Deputy Editor, Endpoints News
1
by Kyle LaHucik

Mer­ck’s $1.3 bil­lion up­front bet on Eye­Bioin 2024 is start­ing to pay off with an ef­fi­ca­cy win, though an­a­lysts ques­tioned safe­ty re­sults from a...

Read the full story
2
by Max Gelman

Aca­dia Phar­ma­ceu­ti­cals re­port­eda Phase 2 fail­ure in Alzheimer’s dis­ease psy­chosis, but the com­pa­ny said it saw enough sig­nal to con­tin­ue for­ward in­to Phase 3...

Read the full story
3
by Anna Brown

Roche is en­ter­ing two fresh part­ner­ships with drug dis­cov­ery biotechs Atavis­tik Bio and Earendil Labs to de­vel­op new can­di­dates, in a con­tin­u­a­tion of the Swiss...

Read the full story
News Briefing: Quick hits from the biopharma web
4
by ENDPOINTS

Plus news about Fra­zier Life Sci­ences, BigHat Bio­sciences, Kasvu Ther­a­peu­tics, Arc­turus Ther­a­peu­tics, Oru­ka Ther­a­peu­tics and Viking Ther­a­peu­tics.

Sarep­ta Ther­a­peu­tics set­tles gene ther­a­py suit:Sarep­ta has...

Read the full story
5
by Elizabeth Cairns

Eli Lil­ly has signed up Bei­jing-based In­no­Care to de­vel­op new med­i­cines in a part­ner­ship that could be worth up to $3.35 bil­lion if the prod­ucts...

Read the full story
Warner Biddle, Kyverna Therapeutics CEO